Analysis: Investors await committee review of EPO drugs

02/6/2008 | RPM Report (free registration), The

Analysts and investors are looking to next month's Oncologic Drugs Advisory Committee meeting for signs of what the market might hold for EPO drugs and Amgen. The committee may discuss removing some cancer indications for the drugs or adding restrictions and requirements for manufacturers, as well as weigh in on Amgen's revised risk-management plan and address potential new safety studies, according to this RPM Report analysis.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ